High concentrations of pyridoxal stimulate the expression of IGFBP1 in HepG2 cells through upregulation of the ERK/c‑Jun pathway.
Increasing evidence suggests that dietary vitamin B6 is linked to the prevention of cancer and cardiovascular disease. However, the molecular mechanisms involved in this process are not yet understood. Preliminary results in the current study indicated, following DNA microarray analysis and quantitative PCR, that insulin‑like growth factor‑binding protein 1 (IGFBP1) mRNA is upregulated in HT29 colon carcinoma cells exposed to pyridoxal (PL, 500 µM). IGFBP1 is secreted from the liver and is hypothesized to exert a protective role in the development of cancer and cardiovascular disease. Thus, further experiments were performed to investigate the effect of PL on the expression of IGFBP1 in HepG2 hepatocellular carcinoma cells. The addition of PL (500 µM) markedly increased the expression of IGFBP1 mRNA in HepG2 cells at 6, 12 and 24 h (P<0.01), whereas other vitamers (500 µM), including pyridoxal 5'‑phosphate (PLP), pyridoxine (PN) and pyridoxamine (PM), caused no such effect. The expression of the IGFBP1 protein in the cell lysate and culture medium was elevated in the presence of PL. PL elevated expression of the active form of ERK1 protein, p‑ERK1, and the p‑c‑Jun protein, a downstream factor of ERK. Furthermore, IGFBP1 expression, elevated by PL, was suppressed by PD98059, an ERK inhibitor. Higher expression of IGFBP1 protein by PL was suppressed by cycloheximide. These results suggest that PL may induce the expression of IGFBP1 in hepatoma cells via a mechanism involving the ERK/c‑Jun pathway.
Graduate School of Biosphere Science, Hiroshima University, Higashi‑Hiroshima, Hiroshima 739‑8528, Japan.
Peipei
P
Zhang
Sofya
S
Suidasari
Tomomi
T
Hasegawa
Noriyuki
N
Yanaka
Norihisa
N
Kato
D049109:Cell Proliferation / Q000187:drug effects; D003513:Cycloheximide / Q000494:pharmacology; D019073:HT29 Cells; D056945:Hep G2 Cells; D006801:Humans; D018970:Insulin-Like Growth Factor Binding Protein 1 / Q000235:genetics / Q000378:metabolism*; D020935:MAP Kinase Signaling System; D014176:Protein Biosynthesis / Q000187:drug effects; D011500:Protein Synthesis Inhibitors / Q000494:pharmacology; D011730:Pyridoxal / Q000494:pharmacology* / Q000502:physiology; D015533:Transcriptional Activation / Q000187:drug effects; D015854:Up-Regulation; D014803:Vitamin B Complex / Q000494:pharmacology* / Q000502:physiology
C032231:IGFBP1 protein, human; D018970:Insulin-Like Growth Factor Binding Protein 1; D011500:Protein Synthesis Inhibitors; D014803:Vitamin B Complex; D011730:Pyridoxal; D003513:Cycloheximide